{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:59:32Z","timestamp":1784033972145,"version":"3.55.0"},"reference-count":24,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Montpellier University Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: Direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection have been proven safe and effective in cirrhotic patients awaiting liver transplantation (LT). However, in the long term, data remain minimal regarding the clinical impact of viral eradication on patients listed for decompensated cirrhosis or hepatocellular carcinoma (HCC). We aimed to elucidate the clinical outcomes of patients regarding delisting and the evolution of HCC during the long-term follow-up. Methods: An observational, multicenter, retrospective analysis was carried out on prospectively collected data from HCV-positive patients treated with an interferon-free regimen while awaiting LT in 18 French hospitals. Results: A total of 179 patients were included in the study. The indication for LT was HCC in 104 (58.1%) patients and cirrhosis in 75 (41.9%) patients. The sustained virological response was 84.4% and the treatment was well tolerated. At five years, among 75 patients with cirrhosis treated for HCV, 19 (25.3%) were delisted following improvement after treatment. Predictive factors for delisting highlighted an absence of ascites, MELD score \u2264 15, and Child\u2013Pugh score \u2264 7. No patients with refractory ascites were delisted. Among patients with HCC, 82 (78.9%) were transplanted. The drop-out rate was low (6.7%) and few recurrences of HCC after LT were observed. Conclusions: DAAs are safe and effective in patients awaiting LT for cirrhosis or HCC. A quarter of patients with cirrhosis can be delisted because of clinical improvement. Predictive factors for delisting, as a result of improvement, may assist prescribers, before initiating HCV infection therapy in the long-term perspective.<\/jats:p>","DOI":"10.3390\/v15010137","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T02:23:06Z","timestamp":1672626186000},"page":"137","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5697-286X","authenticated-orcid":false,"given":"Lucy","family":"Meunier","sequence":"first","affiliation":[{"name":"Montpellier Saint Eloi University Hospital, 80 Avenue Augustin Fliche, 34090 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Belkacemi","sequence":"additional","affiliation":[{"name":"Nouvelles Technologies, AESIO Sant\u00e9, 34070 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Philippe","family":"Pageaux","sequence":"additional","affiliation":[{"name":"Montpellier Saint Eloi University Hospital, 80 Avenue Augustin Fliche, 34090 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Radenne","sequence":"additional","affiliation":[{"name":"Croix-Rousse Hospital, Lyon University Hospital, 103 Grande Rue de la Croix-Rousse, 69004 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Vallet-Pichard","sequence":"additional","affiliation":[{"name":"Cochin Hospital, Public Hospitals of Paris, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Houssel-Debry","sequence":"additional","affiliation":[{"name":"Pontchaillou University Hospital, 2 Rue Henri le Guilloux, 35000 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Duvoux","sequence":"additional","affiliation":[{"name":"Henri-Mondor University Hospital, Public Hospitals of Paris, 51 Avenue du Mar\u00e9chal de Lattre de Tassigny, 94010 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Botta-Fridlund","sequence":"additional","affiliation":[{"name":"Marseille Public Hospital, Timone University Hospital, 264 Rue Saint Pierre, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"de Ledinghen","sequence":"additional","affiliation":[{"name":"Hepatology and Liver Transplantation Unit, Haut-L\u00e9v\u00eaque Hospital, Bordeaux University Hospital, 33600 Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Conti","sequence":"additional","affiliation":[{"name":"Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, Public Hospitals of Paris, 47-83 Boulevard de l\u2019H\u00f4pital, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-9805","authenticated-orcid":false,"given":"Rodolphe","family":"Anty","sequence":"additional","affiliation":[{"name":"Archet 2 Hospital, Nice University Hospital, 151 Route de Saint-Antoine, 06200 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Di Martino","sequence":"additional","affiliation":[{"name":"Besan\u00e7on Regional University Hospital, 3 Boulevard Alexandre Fleming, 25000 Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyne","family":"Debette-Gratien","sequence":"additional","affiliation":[{"name":"Limoges University Hospital, 2 Avenue Martin Luther King, 87000 Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9pato-Gastroent\u00e9rologie, P\u00f4le Digidune, CHU Grenoble Alpes, 38700 La Tronche, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theophile","family":"Gerster","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9pato-Gastroent\u00e9rologie, P\u00f4le Digidune, CHU Grenoble Alpes, 38700 La Tronche, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lebray","sequence":"additional","affiliation":[{"name":"Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, Public Hospitals of Paris, 47-83 Boulevard de l\u2019H\u00f4pital, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Alric","sequence":"additional","affiliation":[{"name":"Rangueil Hospital, Toulouse 3 University Hospital, 31000 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-1052","authenticated-orcid":false,"given":"Armand","family":"Abergel","sequence":"additional","affiliation":[{"name":"Gabriel-Montpied Hospital, Clermont-Ferrand University Hospital, 58 Rue Montalembert, 63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Dumortier","sequence":"additional","affiliation":[{"name":"Edouard Herriot Hospital, Lyon University Hospital, 5 Place d\u2019Arsonval, 69003 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Besch","sequence":"additional","affiliation":[{"name":"Hautepierre Hospital, Strasbourg University Hospital, 1 Avenue Moli\u00e8re, 67200 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Montialoux","sequence":"additional","affiliation":[{"name":"Rouen University Hospital, 37 Boulevard Gambetta, 76000 Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[{"name":"Paul-Brousse Hospital, Public Hospsitals of Paris, 12 Avenue Paul Vaillant Couturier, FHU H\u00e9patinov, 94800 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Duclos-Vall\u00e9e","sequence":"additional","affiliation":[{"name":"Paul-Brousse Hospital, Public Hospsitals of Paris, 12 Avenue Paul Vaillant Couturier, FHU H\u00e9patinov, 94800 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3149-8617","authenticated-orcid":false,"given":"Audrey","family":"Coilly","sequence":"additional","affiliation":[{"name":"Paul-Brousse Hospital, Public Hospsitals of Paris, 12 Avenue Paul Vaillant Couturier, FHU H\u00e9patinov, 94800 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jhep.2017.03.006","article-title":"ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients","volume":"67","author":"Belli","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1053\/jhep.2000.17924","article-title":"Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation","volume":"32","author":"Berenguer","year":"2000","journal-title":"Hepatol. Baltim. Md."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jhep.2004.06.029","article-title":"Fibrosis progression after liver transplantation in patients with recurrent hepatitis C","volume":"41","author":"Neumann","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study","volume":"65","author":"Belli","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation","volume":"67","author":"Pascasio","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/hep.27937","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis","volume":"62","author":"Aqel","year":"2015","journal-title":"Hepatol. Baltim. Md."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29054","article-title":"The dynamic landscape of liver transplant in the era of effective hepatitis C virus therapy","volume":"65","author":"Verna","year":"2017","journal-title":"Hepatol. Baltim. Md."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jvh.12534","article-title":"Treat chronic hepatitis C virus infection in decompensated cirrhosis\u2014Pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy","volume":"23","author":"Bunchorntavakul","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jhep.2016.07.030","article-title":"Reply to \u201cA strong message is needed to address the issue of HCC recurrence after DAA therapy\u201d","volume":"65","author":"Carrat","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"ANRS Collaborative Study Group on Hepatocellular Carcinoma (2016). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J. Hepatol., 65, 734\u2013740.","DOI":"10.1016\/j.jhep.2016.05.045"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: A model including \u03b1-fetoprotein improves the performance of Milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2017.08.025","article-title":"Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything","volume":"68","author":"Mazzarelli","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2017.02.027","article-title":"Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma","volume":"67","author":"Beste","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/hep.29097","article-title":"Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry","volume":"65","author":"Lens","year":"2017","journal-title":"Hepatol. Baltim. Md."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/liv.13878","article-title":"Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting","volume":"38","author":"Perricone","year":"2018","journal-title":"Liver Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/jvh.12877","article-title":"The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities","volume":"25","author":"Cortesi","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1600-6143.2009.02571.x","article-title":"Survival benefit-based deceased-donor liver allocation","volume":"9","author":"Schaubel","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/2050640619840149","article-title":"Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges","volume":"7","author":"Ekpanyapong","year":"2019","journal-title":"United Eur. Gastroenterol. J."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/1\/137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:49:13Z","timestamp":1760147353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/1\/137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["v15010137"],"URL":"https:\/\/doi.org\/10.3390\/v15010137","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]}}}